Effects of sex, treatment resistance, and antidepressant treatment on monoamine oxidase B total distribution volume
This study utilized PET imaging to reveal that females exhibit higher MAO-B levels than males and that treatment-resistant depression is associated with elevated prefrontal MAO-B levels that are insensitive to standard antidepressants but highly responsive to MAO-B inhibitors like rasagiline and phenelzine.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human brain, tiny structures called astrocytes act as support staff for neurons, helping to maintain the environment where thoughts and feelings are generated. Among the many proteins these cells produce is an enzyme known as monoamine oxidase B, or MAO-B. This enzyme performs a specific chemical job: it breaks down certain mood-related chemicals that are not serotonin. In doing so, it also creates a byproduct called hydrogen peroxide, which can be harmful to cells if it builds up. Scientists have long suspected that when MAO-B levels get too high, it may contribute to the development of depression and other serious brain conditions like Alzheimer's disease. The question has been whether this enzyme behaves differently in men and women, and whether its levels change in people whose depression does not respond to standard treatments.
A team of researchers at the Centre for Addiction and Mental Health in Toronto set out to answer these questions by looking directly at the brains of living people. They used a special imaging technique that allows scientists to see how much of a specific protein is present in different brain regions. They studied ninety-five adults, dividing them into three groups: healthy people, people currently experiencing a major depressive episode who had never failed a standard treatment, and people with treatment-resistant depression, meaning their condition had not improved after trying at least two different classes of antidepressant medications. The researchers were particularly interested in the prefrontal cortex, a region at the front of the brain involved in decision-making and mood regulation, as well as other deep brain structures.
The study produced a result that surprised the scientists. They had expected that men might have higher levels of this enzyme, based on previous theories about hormones, but the data showed the opposite. Women had significantly higher levels of MAO-B across the grey matter of the brain, including the prefrontal cortex, compared to men. This difference was substantial, with women showing about ten percent more of the enzyme in these areas. This finding suggests that the biological landscape of the brain differs between the sexes in a way that could help explain why certain brain illnesses, such as Alzheimer's disease and major depression, appear more frequently or follow different paths in women.
When the researchers compared the brains of people with treatment-resistant depression to those with depression that responds to treatment, they found another clear distinction. The group with treatment-resistant depression had much higher levels of MAO-B in the prefrontal cortex than both the healthy volunteers and the people whose depression was not resistant to treatment. Specifically, the enzyme levels were twenty-three percent higher in the resistant group compared to healthy people, and six percent higher than in the non-resistant group. This suggests that a high level of this enzyme might be a key factor that makes some cases of depression so difficult to treat with standard medications.
To test whether this enzyme could be a target for new treatments, a smaller group of participants took part in a trial where they were given different medications. Some took duloxetine, a common antidepressant that works by increasing serotonin and norepinephrine. Others took rasagiline or phenelzine, drugs that are designed to block the activity of MAO-B. The results were stark. The common antidepressant, duloxetine, had almost no effect on the levels of the enzyme. In contrast, the drugs that block MAO-B worked with remarkable efficiency. After taking rasagiline or phenelzine, the amount of the enzyme detected in the brain dropped by about ninety-four percent. This means that at the doses used in the study, these medications successfully occupied and blocked nearly the entire supply of the enzyme in the brain.
These findings point toward a new way of thinking about treatment-resistant depression. Since standard antidepressants do not lower MAO-B levels, and since high levels of this enzyme are linked to the resistant form of the illness, blocking the enzyme directly might offer a solution for those who have not found relief elsewhere. The study confirms that drugs like rasagiline, which are already used for Parkinson's disease, can effectively block this enzyme in the human brain at safe, clinical doses. While the research does not prove that these drugs will cure resistant depression, it provides a strong biological reason to investigate them further for this specific group of patients. The discovery of higher enzyme levels in women also opens a new avenue for understanding why brain health and disease progression can differ so significantly between the sexes.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.